Vaccine has limited efficacy against mild South African variant of virus AstraZeneca and Oxford University rush to improve

Wuhan pneumonia (new coronavirus disease, COVID-19) Epidemic is still rampant in the world, countries continue to vaccination operations, but recently it is rumored that the vaccine developed by the University of Oxford in cooperation with British pharmaceutical manufacturer AstraZeneca has limited efficacy for mild symptoms of the South African variant of the virus, Oxford University and AstraZeneca also said that the vaccine has begun to improve.

According to a study conducted by the University of Witwatersrand and the University of Oxford, the vaccine is not highly effective against the South African variant, while AstraZeneca also mentioned that it tested the effectiveness of the AstraZeneca vaccine against the South African variant “B.1.351” in a small test, and the results showed that the AstraZeneca vaccine had limited efficacy against mild symptoms. The results showed that the AstraZeneca vaccine had limited efficacy against mild symptoms, but an AstraZeneca spokesperson also mentioned that the impact on patients with severe disease could not be determined at this Time.

The AstraZeneca spokesman said that Oxford University and AstraZeneca have already started to improve the vaccine and will work quickly through clinical trials in order to be ready for delivery this fall.